



**SOLVE
ON.**

Incyte Provides Update on Sun Pharmaceuticals, Inc. Litigation

WILMINGTON, Del. – July 14, 2025 – Incyte (Nasdaq:INCY) today announced a successful settlement of its patent dispute regarding Sun Pharmaceutical’s Leqselvi™ (deuruxolitinib). This positive outcome aligns with Incyte’s long-term business objectives.

Under the terms of the settlement agreement, Incyte and Sun will seek dismissal of the pending Leqselvi litigation in the United States District Court for the District of New Jersey, and the Companies will mutually release each other of all claims that were raised or could have been raised in that litigation. Additionally, as part of the agreement, Incyte has granted Sun a limited, non-exclusive license with respect to oral deuruxolitinib (U.S. Patent Nos. 9,662,335 and certain other related patents) for certain agreed-upon non-hematology-oncology indications in the U.S., including alopecia areata.

In exchange for the limited license, Sun will pay Incyte an upfront amount plus ongoing royalty payments. Other specific terms of the settlement and license agreement will remain confidential.

About Incyte

A global biopharmaceutical company on a mission to *Solve On*, Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit [incyte.com](https://www.incyte.com) or follow us on social media: [LinkedIn](#), [X](#), [Instagram](#), [Facebook](#), [YouTube](#).

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this statement, including statements regarding whether and when the Company will pursue any further options in this litigation, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including those risks detailed in the Company’s reports filed with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.

#

Contacts:

Media
media@incyte.com

Investors
ir@incyte.com